Skip to main content

Errata - English

PDF CSV September 15, 2023 through September 15, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE Assay USP35–NF30 1822 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 2: Change
Hypromellose 2906, except to substitute Low-Substituted Hydroxypropyl Cellulose for Hypromellose 2906 throughout.
to:
Hypromellose, except to substitute Low-Substituted Hydroxypropyl Cellulose for Hypromellose throughout.
MYRISTYL ALCOHOL SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> USP35–NF30 1873 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 7 of Analysis: Change
Result = [(VUVB) × F]/W
VU = volume of 1 N sodium hydroxide consumed by the Sample (mL)
VB = volume of 1 N sodium hydroxide consumed by the Blank (mL)… Read More
AMANTADINE HYDROCHLORIDE CAPSULES PERFORMANCE TESTS/Dissolution <711>/Test 2 USP35–NF30 2153 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 5 of Chromatographic system: Change
Column: 0.32-mm × 30-cm, 0.25-μm film, phase G1
to:
Column: 0.32-mm × 30-m, 0.25-μm film, phase G1
CAPTOPRIL ORAL SOLUTION Assay USP35–NF30 2477 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid.
to:
Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
LORATADINE ORALLY-DISINTEGRATING TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards USP35–NF30 3714 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 4 of USP Reference Standards: Change
8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine.
to:
8-Chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine.
AND
Line 6: Change
310.83… Read More
NORGESTIMATE Limit of residual solvents USP35–NF30 4083 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Limit of residual solvents: Change
to:
Limit of residual solvents <467>
ONDANSETRON INJECTION USP Reference Standards USP35–NF30 4120 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 7: Delete
USP Ondansetron Related Compound B RS
6,6´-Methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one.
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP35–NF30 4167 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 3 of Working standard solution: Change
or transfer 10 mL for Tablets labeled to contain 10 mg, to a 100-mL volumetric flask.
to:
transfer 10 mL for Tablets labeled to contain 10 mg, or transfer 15 mL for Tablets labeled to contain 15 mg to a 100-mL volumetric flask.
PHENYLALANINE IMPURITIES USP35–NF30 4296 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Heavy Metals, Method I <231>: Change
Method I
to:
Method II
TRIAZOLAM TABLETS Assay USP35–NF30 4936 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 2: Change
Mobile phase and Chromatographic system—Proceed as directed in the Assay under Triazolam.
to:
Mobile phase—Prepare a filtered and degassed mixture of acetonitrile, chloroform, butyl alcohol, water, and glacial acetic acid (850:80:50:20:0.5… Read More
VINCRISTINE SULFATE IMPURITIES/Organic Impurities USP35–NF30 5022 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 5 of Analysis: Change
Result = [rUA/(ΣrUA + 25rUB)] × 100
to:
Result = [rUA/(ΣrUA + 30rUB)] × 100
AND
Change line 12 of… Read More
ZINC GLUCONATE IMPURITIES/Limit of Cadmium USP35–NF30 5070 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 22 of Analysis: Change
W = weight of Calcium Gluconate taken to prepare Sample solution A (g)
to:
W = weight of Zinc Gluconate taken to prepare Sample solution A (g)
ALLANTOIN IDENTIFICATION First Supplement to USP35–NF30 5429 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of B. Thin-Layer Chromatographic Identification Test <201>: Change
The RF value of the principal spot from Sample solution A corresponds to that from Standard solution A, as described in the test for Organic Impurities.
to:
The… Read More
<232> ELEMENTAL IMPURITIES--LIMITS Drug Products/Large Volume Parenterals Second Supplement to USP35–NF30 5633 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Row 16 of Column 4 of Table 1: Change
70
to:
100
AND
Row 16 of Column 5 of Table 1: Change
25
to:
10
AZITHROMYCIN FOR INJECTION IMPURITIES/Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3’-De(dimethylamino)-3’-oxoazithromycin (if present) Second Supplement to USP35–NF30 5910 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Buffer: Change
3.5 g/mL
to:
3.5 g/L
ADAPALENE IMPURITIES/Residual Solvent: Limit of Triethylamine Revision Bulletin (Official December 01, 2012) Online 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Diluent: Change
Dimethyl sulfoxide and 1 N sodium hydroxide solution (4:1)
to:
Dimethyl sulfoxide
AND
Line 1 of Standard solution: Change
3.2 μg/mL of USP Triethylamine RS in Diluent
to:
4.0 μg/mL of USP Triethylamine RS in Diluent.… Read More
TACROLIMUS ORAL SUSPENSION ASSAY/Chromatographic system USP36–NF31 5261 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 After line 1 of Column: Add a new section
Column temperature: 70°
CAPTOPRIL ORAL SUSPENSION Assay USP35–NF30 2477 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid.
to:
Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
<232> ELEMENTAL IMPURITIES--LIMITS Drug Substance and Excipients Second Supplement to USP35–NF30 5633 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Row 16 of Column 4 of Table 2: Change
7
to:
10
Olanzapine Tablets ASSAY/Procedure Revision Bulletin (Official July 01, 2012) Online 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 10 of Analysis: Change
CU = concentration of olanzapine in the Sample solution (mg/mL)
to:
CU = nominal concentration of olanzapine in the Sample solution (mg/mL)
Olanzapine Tablets IMPURITIES/Organic Impurities Revision Bulletin (Official July 01, 2012) Online 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 11 of Analysis: Change
CU = concentration of olanzapine in the Sample solution (mg/mL)
to:
CU = nominal concentration of olanzapine in the Sample solution (mg/mL)
Olanzapine Tablets ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Revision Bulletin (Official July 01, 2012) Online 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Lines 3 and 6: Change
USP Olanzapine Related Compound A RS
5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile.
USP Olanzapine Related Compound B RS
2-Methyl-10H-thieno-[2,3-b][1,5]benzodiazepin-4[5H]-one.
to:
USP Olanzapine Related Compound A RS
5… Read More
<81> Antibiotics—Microbial Assays Turbidimetric Method USP35–NF30 74 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 8 of Analysis: Change
Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see Table 8) but no antibiotic.
to:
Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see Table 7) but no antibiotic.
Polysorbate 80 SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> USP35–NF30 1920 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 13 of Analysis: Change
0.5 N alcoholic potassium hydroxide
to:
0.5 N alcoholic potassium hydroxide VS
Polysorbate 80 SPECIFIC TESTS/Fats and Fixed Oils, Peroxide Value <401> USP35–NF30 1920 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 5 of Analysis: Change
0.01 M sodium thiosulfate
to:
0.01 M sodium thiosulfate VS
Polysorbate 80 SPECIFIC TESTS/Fats and Fixed Oils, Saponification Value <401> USP35–NF30 1920 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 3 of Analysis: Change
0.5 N alcoholic potassium hydroxide
to:
0.5 N alcoholic potassium hydroxide VS

Line 6 of Analysis: Change
0.5 N hydrochloric acid
to:
0.5 N hydrochloric acid VS
Aminosalicylate Sodium Limit of m-aminophenol USP35–NF30 2177 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Test preparation: Change
Use the Assay preparation, prepared as directed in the Assay.
to:
Transfer about 69 mg of Aminosalicylate Sodium, accurately weighed, to a 100-mL low-actinic volumetric flask, add 50 mL of Mobile phase, and swirl to dissolve.… Read More
Aminosalicylate Sodium Tablets Limit of m-aminophenol USP35–NF30 2178 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Test solution: Change
Use the Assay preparation, prepared as directed in the Assay.
to:
Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL… Read More
Aminosalicylic Acid Tablets Limit of m-aminophenol USP35–NF30 2179 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Change the subsection:
Mobile phase and Internal standard solution—Prepare as directed in the Assay under Aminosalicylic Acid.
to:
Mobile phase—Prepare as directed in the Assay under Aminosalicylic Acid.
Internal standard solution… Read More
Ampicillin Sodium SPECIFIC TESTS/pH <791> USP35–NF30 2213 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 2: Change text of Sample solution from
10.0 mg/mL
to:
10.0 mg/mL of ampicillin
Budesonide ASSAY/Procedure USP35–NF30 2394 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 2 of Acceptance criteria: Change
Epimer A: 40.0%–51.0% on the dried basis
to:
Epimer A: 40.0%–51.0%
Dibasic Calcium Phosphate Dihydrate ASSAY USP35–NF30 2463 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 14 of Analysis: Change
W = Sample weight (mg)
to:
W = Sample weight (mg) in 20.0 mL of the Sample solution
Dibasic Calcium Phosphate Dihydrate IMPURITIES/Heavy Metals, Method I <231> USP35–NF30 2463 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Test preparation: Change
Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve.
to:
Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Anhydrous Dibasic Calcium Phosphate ASSAY USP35–NF30 2464 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 In line 14 of Analysis: Change
W = Sample weight (mg)
to:
W = Sample weight (mg) in 20.0 mL of the Sample solution
Anhydrous Dibasic Calcium Phosphate IMPURITIES/Heavy Metals, Method I <231> USP35–NF30 2464 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Test preparation: Change
Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve.
to:
Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Cod Liver Oil ASSAY/Vitamin D USP35–NF30 2756 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Aqueous potassium hydroxide solution: Change
Dissolve 800 mg of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool.
to:
Dissolve 800 g of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool.
Glimepiride Tablets PERFORMANCE TESTS/Dissolution/Test 1 USP35–NF30 3335 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 3 of Analysis: Change
Result = (rU/rS) × (CS/L) × V × 100
to:
Result = (rU/rS) × (CS/L) × V × D x 100
AND after Line 8 of Analysis:… Read More
Moxifloxacin Ophthalmic Solution Related compounds/Test 1 USP35–NF30 3960 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 4 of Chromatographic system: Delete
The flow rate is about 0.5 mL per minute.
Metronidazole ASSAY USP36–NF31 4352 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 8 of Chromatogaphic system: Add new subsection after Injection volume:
Run time: Twice the retention time of metronidazole
Tramadol Hydrochloride Tablets IMPURITIES/Organic Impurities/Procedure USP35–NF30 4905 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 5 of Analysis: Change
Result = (rU/rS) × (CS/CU) × (1/F) × 0.1
to:
Result = (rU/rS) × (CS/CU) × (1/F) × 100
Triclosan Related compounds USP35–NF30 4939 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Procedure: Change
Inject a volume (about 0.5 µL)
to:
Inject a volume (about 2.0 µL)
Compound Undecylenic Acid Ointment Assay for zinc undecylenate USP35–NF30 4978 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 17 of Procedure: Change
AU, AH, and AL
to:
AU, AS1, and AS2
<660> Containers—Glass SPECIFIC TESTS/Hydrolytic Resistance/Method First Supplement to USP35–NF30 5150 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 In the Note in line 11 of Titration: Change
Rinse the grains by swirling with three 15-mL portions of Purified Water, and add the washings to the main solution.
to:
Rinse the grains by swirling with three 15-mL portions of Carbon Dioxide-Free Water, and add the washings to the main… Read More
Esomeprazole Magnesium Delayed-Release Capsules ASSAY/Procedure First Supplement to USP35–NF30 5473 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Standard solution: Change
Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of methanol.
to:
Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of alcohol.
Esomeprazole Magnesium Delayed-Release Capsules PERFORMANCE TESTS/Dissolution <711> First Supplement to USP35–NF30 5473 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Change
Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system: Proceed as directed in the Assay.
to:
Buffer, Mobile phase, System suitability, and Chromatographic system: Proceed as directed in the Assay.
Esterified Estrogens Tablets ASSAY/Procedure First Supplement to USP35–NF30 5485 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 3 of Analysis: Change
Separately calculate the percentage of the labeled amount of sodium estrone sulfate and sodium equilin sulfate in the portion of Conjugated Estrogens taken:
to:
Separately calculate the percentage of the labeled amount of sodium estrone sulfate and… Read More
Itraconazole IMPURITIES/Organic Impurities First Supplement to USP35–NF30 5508 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Standard solution: Change
1.0 µg/mL of USP Itraconazole RS in Diluent
to:
10.0 µg/mL of USP Itraconazole RS in Diluent
Omega-3-Acid Ethyl Esters Capsules SPECIFIC TESTS/Microbial Enumeration <61> First Supplement to USP35–NF30 5524 1-Dec-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2: Change
103
to:
103 cfu/g
AND
Line 3: Change
102
to:
102 cfu/g
Carisoprodol Tablets ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP35–NF30 5921 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 5: At end of USP Reference Standards, add
USP Meprobamate RS
Cefepime Hydrochloride IMPURITIES/Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine Second Supplement to USP35–NF30 5923 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 5 of Chromatographic system: Change
Column: 4.0-mm x 25-cm; 5-µm packing L##1
to:
Column: 4.0-mm x 25-cm; 5-µm packing L76
AND
Delete corresponding footnote: "Available as Metrosep C4-250."